Purpose: Intensity-modulated radiation therapy (IMRT) utilizes many small fields for producing a uniform dose distribution. Therefore, there are many field junctions in the target region, and resulting dose uncertainties are accumulated. However, such accumulation of the dose uncertainty has not been implemented in the current practice of IMRT dose verification. The purpose of this study is to develop a method to predict the gamma passing rate (GPR) using a dose uncertainty accumulation model.
Methods: Thirty-three intensity-modulated (IM) beams for head-and-neck cases with step-and-shoot techniques were used in this study. The treatment plan was created using the XiO treatment planning system (TPS). The IM beam was produced by the ONCOR Impression Plus linear accelerator. MapCHECK was used to measure the dose distribution. The distribution of a dose uncertainty potential (DUP) was generated by in-house software that accumulated field shapes weighted by a segmental monitor unit, followed by Gaussian folding. The width of the Gaussian was determined from the width of the lateral penumbra. The dose difference between the calculated and measured doses was compared with the estimated DUP at each point. The GPR of each beam was predicted for 2%/2-mm, 3%/2-mm, and 3%/3-mm tolerances by its own DUP histogram and a GPR-vs-DUP correlation of other beams using the leave-one-out cross-validation method. The predicted GPR was compared with the measured GPR to evaluate the performance of this prediction method. The criteria for the predicted GPR corresponding to a measured GPR ≥ 90% were estimated to examine the feasibility of estimating the measured GPR by this GPR prediction method.
Results: The DUP was confirmed to have proportionality to the standard deviation (SD) of the dose difference. The SDs of the difference between the measured and predicted GPRs were 3.1, 1.7, and 1.4% for 2%/2-mm, 3%/2-mm, and 3%/3-mm tolerances, respectively. The criteria of the predicted GPR corresponding to the measured GPR ≥ 90% were 94.1 and 95.0% with confidence levels of 99 and 99.9%, respectively.
Conclusion: In this study, we confirmed the good proportionality between the dose difference and the estimated DUP. The results showed a feasibility to predict the dose difference from DUP as estimated by a DUP accumulation model. The predicted GPR developed in this study showed good accuracy for planar dose distributions of head and neck IMRT. The prediction method developed in this study is considered to be feasible as a substitute for the current practice of measurement-based verification of the dose distribution with gamma analysis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/mp.13333 | DOI Listing |
Toxicol Sci
January 2025
ToxStrategies LLC, Austin, Texas, USA.
Traditional approaches for quantitatively characterizing uncertainty in risk assessment require adaptation to accommodate increased reliance on observational (vs. experimental) studies in developing toxicity values. Herein, a case study with PFOA and PFOS and vaccine response explores approaches for qualitative and-where possible-quantitative assessments of uncertainty at each step in the toxicity value development process when using observational data, including review and appraisal of individual studies, candidate study selection, dose-response modeling, and application of uncertainty factors.
View Article and Find Full Text PDFRadiother Oncol
January 2025
Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Medical Artificial Intelligence and Automation Laboratory, Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA. Electronic address:
Background And Purpose: Daily online adaptive radiotherapy (DART) increases treatment accuracy by crafting daily customized plans that adjust to the patient's daily setup and anatomy. The routine application of DART is limited by its resource-intensive processes. This study proposes a novel DART strategy for head and neck squamous cell carcinoma (HNSCC), automizing the process by propagating physician-edited treatment contours for each fraction.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Integrative Pharmacology and Systems Neurosciences Research Group, Neurosciences Research Program, Hospital del Mar Research Institute, Barcelona, Spain.
Background: Adhering to lifestyle-based multimodal interventions to prevent cognitive decline is crucial for their success, but limited evidence exists on determinants of adherence. This gap may stem from inconsistent adherence measurement and reporting across studies. Additionally, uncertainties persist regarding the optimal intervention intensity needed for meaningful cognitive benefits.
View Article and Find Full Text PDFBackground: The β-secretase-1 inhibitors (BACEi), including verubecestat, were extensively studied in prodromal to moderate AD and demonstrated early cognitive decline (negative effect) at doses achieving >50% inhibition of amyloid production. Questions remain as to whether BACEi may still have utility, if used earlier in disease and at lower levels of inhibition. A mechanistic model of the progression of Alzheimer's disease was used to predict effects of alternative BACEi therapeutic approaches on disease progression.
View Article and Find Full Text PDFMed Phys
January 2025
Department of Nuclear Medicine and Medical Physics, Karolinska University Hospital, Stockholm, Sweden.
Background: Modern reconstruction algorithms for computed tomography (CT) can exhibit nonlinear properties, including non-stationarity of noise and contrast dependence of both noise and spatial resolution. Model observers have been recommended as a tool for the task-based assessment of image quality (Samei E et al., Med Phys.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!